Researching for solutions to Alzheimer’s, stroke

G. Mugesh wins the Infosys Prize 2019 in physical sciences

November 08, 2019 12:34 am | Updated 09:09 am IST - Bengaluru

Infosys Prize winner G. Mugesh at a press meet in Bengaluru on Thursday. Sudhakara Jain

Infosys Prize winner G. Mugesh at a press meet in Bengaluru on Thursday. Sudhakara Jain

Growing up in a family of agriculturists in a village in Salem, Tamil Nadu, G. Mugesh, professor, Department of Inorganic and Physical Chemistry, Indian Institute of Science (IISc.), Bengaluru, was educated in government schools and colleges.

His stint at IIT Bombay was the turning point for him, he said at the event where it was announced that he was one of six winners of the Infosys Prize 2019 by the Infosys Science Foundation (ISF) on Thursday,

He won the award in the category of Physical Sciences for his work in the chemical synthesis of small molecules and nanomaterials for biomedical applications.

According to the official release, his work has contributed to the understanding of the role of trace elements, selenium and iodine, in thyroid hormone activation and metabolism, and this research has led to major medical advances.

Prof. Mugesh’s research involves designing new molecules that can regulate the biological systems in the cells. “We will be working on two areas — developing compounds that can regulate the biological system under disease conditions, such as endothelial dysfunction, which is the beginning of heart attack. We are trying to make small molecules to regulate the biological system which can actually work as a treatment for this disease. The second area is developing compounds to treat stroke neuro degeneration. Metal ions play a very important role. The human body has around 66 gm of iron. But if disregulated, for example release of iron in the brain, it causes Alzheimer’s and other diseases. We would like to study how these trace metals control brain function,” he said.

Prof. Mugesh, who has been with the IISc. since 2012, said his aim was to conceptualise a new drug which he would like to take to the clinical trial level.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.